 |
18 Diseases |  |
2 Trials |
|
2 Trials |  |
512 News |  |
| «1234567 |
- |||| Reasanz (serelaxin) / Novartis
Trial completion, Trial primary completion date: Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure (clinicaltrials.gov) - Feb 24, 2016
P2, N=321, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | Trial primary completion date: Apr 2016 --> Sep 2015
- | Reasanz (serelaxin) / Novartis
New P2 trial: STOPP: Serelaxin To Lower Portal Pressure (clinicaltrials.gov) - Feb 1, 2016
P2, N=20, Not yet recruiting, Sponsor: University of Edinburgh
- ||||| Reasanz (serelaxin) / Novartis
New P2 trial: RELAX-Cardio: Study of the Effect of Serelaxin on High-sensitivity Cardiac Troponin I (Hs-cTnI) Release in Patients With Chronic Heart Failure (clinicaltrials.gov) - Dec 10, 2015
P2, N=125, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- || Reasanz (serelaxin) / Novartis
Trial primary completion date: Study of the Vascular Effects of Serelaxin (clinicaltrials.gov) - Oct 6, 2015
P2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | Trial primary completion date: Apr 2016 --> Sep 2015 Trial primary completion date: Jan 2016 --> Aug 2016
- |||| Reasanz (serelaxin) / Novartis
Trial primary completion date: RELAX-AHF-ASIA: Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF (clinicaltrials.gov) - Aug 21, 2015
P3, N=1520, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jan 2016 --> Aug 2016 Trial primary completion date: Sep 2016 --> Mar 2017
- Reasanz (serelaxin) / Novartis
Trial primary completion date: RELAX-PEDS-PK: Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure (clinicaltrials.gov) - Jul 9, 2015
P2, N=36, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Sep 2016 --> Mar 2017 Trial primary completion date: Oct 2015 --> Mar 2016
- | Reasanz (serelaxin) / Novartis
Trial completion, Trial primary completion date: An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension (clinicaltrials.gov) - Apr 1, 2015
P2, N=48, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Oct 2015 --> Mar 2016 Recruiting --> Completed | Trial primary completion date: Mar 2015 --> Dec 2014
- |||| Reasanz (serelaxin) / Novartis
Trial primary completion date: RELAX-AHF-EU: Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients (clinicaltrials.gov) - Feb 10, 2015
P3, N=2685, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed | Trial primary completion date: Mar 2015 --> Dec 2014 Trial primary completion date: Dec 2015 --> Jan 2017
- || Reasanz (serelaxin) / Novartis
Trial primary completion date: Study of the Vascular Effects of Serelaxin (clinicaltrials.gov) - Oct 4, 2014
P2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2015 --> Jan 2017 Trial primary completion date: Aug 2015 --> Jan 2016
- | Reasanz (serelaxin) / Novartis
Enrollment open, Trial initiation date: RELAX-PEDS-PK: Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure (clinicaltrials.gov) - Sep 19, 2014
P2, N=36, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Aug 2015 --> Jan 2016 Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Sep 2014
- | Reasanz (serelaxin) / Novartis
Trial completion: Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients (clinicaltrials.gov) - Aug 28, 2014
P2, N=46, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting | Initiation date: Jun 2014 --> Sep 2014 Active, not recruiting --> Completed
- |||| Reasanz (serelaxin) / Novartis
Trial primary completion date: RELAX-AHF-EU: Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients (clinicaltrials.gov) - Aug 5, 2014
P3, N=2685, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed Trial primary completion date: Jun 2015 --> Dec 2015
- Reasanz (serelaxin) / Novartis
Enrollment change, Trial termination, Trial primary completion date: Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia (clinicaltrials.gov) - Jul 15, 2014
P2, N=3, Terminated, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jun 2015 --> Dec 2015 N=60 --> 3 | Recruiting --> Terminated | Trial primary completion date: Apr 2017 --> Aug 2014; Novartis terminated this study due to internal, strategic decisions.
- | Reasanz (serelaxin) / Novartis
Enrollment closed: Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients (clinicaltrials.gov) - Jul 1, 2014
P2, N=46, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=60 --> 3 | Recruiting --> Terminated | Trial primary completion date: Apr 2017 --> Aug 2014; Novartis terminated this study due to internal, strategic decisions. Recruiting --> Active, not recruiting
- | Reasanz (serelaxin) / Novartis
New P2 trial: RELAX-PEDS-PK: Pharmacokinetics & Safety of Serelaxin on Top of Standard of Care Therapy in Pediatric Patients With Acute Heart Failure (clinicaltrials.gov) - May 27, 2014
P2, N=36, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- || Reasanz (serelaxin) / Novartis
Trial primary completion date: Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure (clinicaltrials.gov) - May 14, 2014
P2, N=300, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Jan 2016 --> Mar 2016
- ||| Reasanz (serelaxin) / Novartis
Trial initiation date: Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure (clinicaltrials.gov) - May 14, 2014
P2, N=300, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Jan 2016 --> Mar 2016 Initiation date: Feb 2014 --> May 2014
- || Reasanz (serelaxin) / Novartis
Trial completion date: Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure (clinicaltrials.gov) - May 14, 2014
P2, N=300, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Feb 2014 --> May 2014 Trial completion date: Jan 2016 --> Mar 2016
- |||| Reasanz (serelaxin) / Novartis
Enrollment open: Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure (clinicaltrials.gov) - May 14, 2014
P2, N=300, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Jan 2016 --> Mar 2016 Not yet recruiting --> Recruiting
- Reasanz (serelaxin) / Novartis
Trial primary completion date: An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension (clinicaltrials.gov) - May 6, 2014
P2, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2014 --> Jan 2015
- Reasanz (serelaxin) / Novartis
Trial completion date: An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension (clinicaltrials.gov) - May 6, 2014
P2, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Sep 2014 --> Jan 2015 Trial completion date: Sep 2014 --> Jan 2015
- Reasanz (serelaxin) / Novartis
Trial termination: Recombinant Human Relaxin for the Treatment of Decompensated CHF (clinicaltrials.gov) - May 5, 2014
P2, N=11, Terminated, Sponsor: Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies
Trial completion date: Sep 2014 --> Jan 2015 Completed --> Terminated
- ||||| Reasanz (serelaxin) / Novartis
Trial initiation date: RELAX-AHF-2: Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF (clinicaltrials.gov) - Apr 14, 2014
P3, N=6375, Ongoing, Sponsor: Novartis Pharma Services AG`Novartis Farma SpA`Novartis Farmac
Completed --> Terminated Initiation date: Oct 2013 --> Nov 2013
- |||||| Reasanz (serelaxin) / Novartis
Enrollment open: RELAX-AHF-ASIA: Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF (clinicaltrials.gov) - Apr 8, 2014
P3, N=1520, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Oct 2013 --> Nov 2013 Not yet recruiting --> Recruiting
- Reasanz (serelaxin) / Novartis
Enrollment change: PK of Serelaxin in Severe Renal Impairment and ESRD (clinicaltrials.gov) - Apr 1, 2014
P1, N=36, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting N=24 --> 36
- | Reasanz (serelaxin) / Novartis
Trial completion: PK of Serelaxin in Severe Renal Impairment and ESRD (clinicaltrials.gov) - Apr 1, 2014
P1, N=36, Completed, Sponsor: Novartis Pharmaceuticals
N=24 --> 36 Recruiting --> Completed
- |||||||||| Reasanz (serelaxin) / Novartis
New P3 trial: RELAX-AHF-EU: Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients (clinicaltrials.gov) - Feb 13, 2014
P3, N=2685, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||| Reasanz (serelaxin) / Novartis
Trial initiation date: Study of the Vascular Effects of Serelaxin (clinicaltrials.gov) - Feb 10, 2014
P2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Initiation date: Nov 2013 --> Feb 2014
- |||| Reasanz (serelaxin) / Novartis
Enrollment open: Study of the Vascular Effects of Serelaxin (clinicaltrials.gov) - Feb 10, 2014
P2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Nov 2013 --> Feb 2014 Not yet recruiting --> Recruiting
- | Reasanz (serelaxin) / Novartis
Enrollment open: Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients (clinicaltrials.gov) - Jan 28, 2014
P2, N=45, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- |||||||||| Reasanz (serelaxin) / Novartis
New P3 trial: RELAX-AHF-ASIA: Efficacy, Safety and Tolerability of Sexelaxin When Added to Standard Therapy in AHF (clinicaltrials.gov) - Dec 9, 2013
P3, N=1520, Recruiting, Sponsor: Novartis Pharmaceuticals
- | Reasanz (serelaxin) / Novartis
New P2 trial: Study of Safety, Tolerability and Pharmacokinetics of Serelaxin in Japanese Acute Heart Failure (AHF) Patients (clinicaltrials.gov) - Dec 4, 2013
P2, N=45, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||||| Reasanz (serelaxin) / Novartis
New P2 trial: Safety of Repeat Doses of IV Serelaxin in Subjects With Chronic Heart Failure (clinicaltrials.gov) - Nov 11, 2013
P2, N=300, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- ||||| Reasanz (serelaxin) / Novartis
New P2 trial: Study of the Vascular Effects of Serelaxin (clinicaltrials.gov) - Nov 6, 2013
P2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||| Reasanz (serelaxin) / Novartis
Enrollment change: Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure (clinicaltrials.gov) - Jun 18, 2013
P2, N=71, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting N=120 --> 71
- | Reasanz (serelaxin) / Novartis
New P1 trial: PK of Serelaxin in Severe Renal Impairment and ESRD (clinicaltrials.gov) - Jun 10, 2013
P1, N=36, Completed, Sponsor: Novartis Pharmaceuticals
- || Reasanz (serelaxin) / Novartis
New P3 trial: RELAX-AHF-2: Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF (clinicaltrials.gov) - Jun 4, 2013
P3, N=6375, Ongoing, Sponsor: Novartis Pharma Services AG`Novartis Farma SpA`Novartis Farmac
- | Reasanz (serelaxin) / Novartis
Enrollment open: An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension (clinicaltrials.gov) - Jun 2, 2013
P2, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
N=120 --> 71 Not yet recruiting --> Recruiting
- Reasanz (serelaxin) / Novartis
Enrollment open: Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia (clinicaltrials.gov) - May 22, 2013
P2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| Reasanz (serelaxin) / Novartis
Enrollment change: Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF) (clinicaltrials.gov) - Feb 6, 2013
P2, N=118, Completed, Sponsor: Novartis Pharmaceuticals
Not yet recruiting --> Recruiting N=88 --> 118
- |||| Reasanz (serelaxin) / Novartis
Trial completion: Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF) (clinicaltrials.gov) - Feb 6, 2013
P2, N=118, Completed, Sponsor: Novartis Pharmaceuticals
N=88 --> 118 Recruiting --> Completed
- |||| Reasanz (serelaxin) / Novartis
Trial completion: Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure (clinicaltrials.gov) - Jan 28, 2013
P2, N=71, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Recruiting --> Completed
- | Reasanz (serelaxin) / Novartis
New P2 trial: An Exploratory Haemodynamic Study in Patients With Compensated Cirrhosis and Portal Hypertension (clinicaltrials.gov) - Jul 12, 2012
P2, N=50, Recruiting, Sponsor: Novartis Pharmaceuticals
- | Reasanz (serelaxin) / Novartis
New P2 trial: Safety and Efficacy of RLX030 in Pregnant Women With Pre- Eclampsia (clinicaltrials.gov) - Mar 27, 2012
P2, N=60, Recruiting, Sponsor: Novartis Pharmaceuticals
- ||||| Reasanz (serelaxin) / Novartis
New P2 trial: Renal Hemodynamic Effects of RLX030A in Subjects With Chronic Heart Failure (CHF) (clinicaltrials.gov) - Mar 5, 2012
P2, N=118, Completed, Sponsor: Novartis Pharmaceuticals
- ||| Reasanz (serelaxin) / Novartis
Trial completion: Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Subjects (clinicaltrials.gov) - Mar 4, 2012
P1, N=55, Completed, Sponsor: Novartis Pharmaceuticals
Recruiting --> Completed Recruiting --> Completed
- ||||| Reasanz (serelaxin) / Novartis
New P2 trial: Hemodynamic Responses to RLX030 Infusion in Subjects With Acute Heart Failure (clinicaltrials.gov) - Mar 1, 2012
P2, N=71, Completed, Sponsor: Novartis Pharmaceuticals
- ||| Reasanz (serelaxin) / Novartis
New P1 trial: Pharmacokinetics of RLX030 in Subjects With Mild, Moderate and Severe Hepatic Impairment Compared to Healthy Subjects (clinicaltrials.gov) - Sep 12, 2011
P1, N=55, Completed, Sponsor: Novartis Pharmaceuticals